Citadel Advisors’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Citadel Advisors’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,191	Closed	-$207	–	13451
2025 Q3	$207	Sell	15,191 -320	-2%	-$5	﹤0.01%	12620
2025 Q2	$335	Buy	+15,511	New	+$307	﹤0.01%	12294
2024 Q3	–	Sell	-13,189	Closed	-$144	–	14791
2024 Q2	$144	Sell	13,189 -15	-0.1%	–	﹤0.01%	14088
2024 Q1	$162	Buy	13,204 +100	+0.8%	+$1	﹤0.01%	14405
2023 Q4	$236	Buy	13,104 +278	+2%	+$3	﹤0.01%	14080
2023 Q3	$190	Buy	+12,826	New	+$265	﹤0.01%	14134

Other funds holding KTTAW

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Citadel Advisors's KTTAW Position: Q4 2025 in Review

Citadel Advisors sold out of Pasithea Therapeutics Warrants (KTTAW) in Q4 2025, closing a stake of 15,191 shares — an estimated $207 sold.

Citadel Advisors first reported a position in KTTAW in Q3 2023 and held it in 6 quarters. The position peaked at $335 in Q2 2025. 4 funds tracked by Wall St. Rank hold KTTAW as of Q4 2025.

Citadel Advisors reported no remaining Pasithea Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 15,191 Pasithea Therapeutics Warrants shares in Q4 2025, an estimated $207.
Citadel Advisors first reported a position in Pasithea Therapeutics Warrants in Q3 2023 and held it in 6 quarters.
Citadel Advisors's Pasithea Therapeutics Warrants position peaked at $335 in Q2 2025.
4 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.